NDAORALTABLET
Approved
Nov 1942
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
DEMEROL (meperidine hydrochloride) by Gen Pharmaceuticals is morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 1942.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Demerol (meperidine hydrochloride) is a synthetic opioid analgesic approved in 1942 for the management of severe pain inadequately controlled by alternative treatments. It works as a mu-opioid receptor agonist with principal therapeutic actions of analgesia and sedation via central nervous system effects.
$0.071MPart D
LOE ApproachingMinimal commercial activity with declining Medicare utilization signals a mature, small-scale team focused on maintenance rather than growth initiatives.
Mechanism of Action
morphine; the most prominent of these involve the central nervous system and organs composed of smooth muscle. The principal actions of therapeutic value are analgesia and sedation.
Worked on DEMEROL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.